PodcastCancer

Science Signaling Podcast: 24 September 2013

Sci. Signal.  24 Sep 2013:
Vol. 6, Issue 294, pp. pc25
DOI: 10.1126/scisignal.2004717

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

This Podcast features an interview with Martin Miller and Chris Sander, authors of a Research Article that appears in the 24 September 2013 issue of Science Signaling. Although anticancer drug treatment may initially kill tumor cells, the cells often acquire resistance to the drug and resume proliferation. One way to reduce the likelihood of resistance and increase drug efficacy is to simultaneously treat tumors with two or more drugs that target different cellular proteins. Miller et al. found that simultaneous inhibition of CDK4 (cyclin-dependent kinase 4) and IGF1R (insulin-like growth factor 1 receptor) synergistically inhibited proliferation of two patient-derived dedifferentiated liposarcoma cell lines. Liposarcomas are tumors that develop from fat cells, and dedifferentiated liposarcoma is a subtype that is particularly aggressive and difficult to treat. The authors then used network modeling to identify the signaling pathways mediating this synergistic effect.

View Full Text

Related Content